Real word outcomes associated with use of raltegravir in older people living with HIV: results from the 60 months follow-up of the RAL-age cohort. Issue 5 (3rd May 2020)

• Record Type: Journal Article
• Authors: Santinelli, Letizia; Ceccarelli, Giancarlo; Borrazzo, Cristian; Celani, Luigi; Pavone, Paolo; Innocenti, Giuseppe Pietro; Spagnolello, Ornella; Fimiani, Caterina; Ceci, Fabrizio; Di Sora, Fiorella; Mezzaroma, Ivano; Mastroianni, Claudio Maria; d'Ettorre, Gabriella
• Is Part Of: Expert review of anti-infective therapy. Volume 18:Issue 5(2020)
• Page Start: 485
• Page End: 492
• Publication Date: 2020-05-03
• Subjects: Efficacy -- immune activation -- metabolism -- raltegravir -- real-life -- tolerability; Anti-infective agents -- Research -- Periodicals; 616.90461
• DOI: 10.1080/14787210.2020.1733415
• Languages: English
• ISSNs: 1478-7210

Abstract

ABSTRACT: Objective : In people living with HIV (PLWH), antiretroviral treatments have increased the median life expectancy. Raltegravir (RAL) represents a long-term safe regimen used both in the first-line antiretroviral treatments and in the optimization strategies. Aim of the study was to evaluate the real-life efficacy, tolerability, and safety of the long-term RAL use in a multicenter cohort of elderly PLWH. Methods : A 60-month follow-up observational study was carried out in the RAL-AGE Cohort including aged PLWH (≥60 years old) treated with RAL-based regimens (n = 96). The control group was a cohort of PLWH aged less than 60 years (n = 50). Results : RAL treated aged HIV population experiences an increase of CD4 + cells and a stable control of viral load at 60 months of follow-up. A significant improvement in lipid metabolism profile, a decrease of platelet count and a reduction in cardiovascular risk levels were observed in the older population. Immune activation markers expressed on CD4 + T cells decreased compared to baseline, but this difference was greater in the control group. Conclusion : A 60-month treatment with RAL-containing regimens is safe and highly effective in the older PLWH and these data give new insights on the elderly population. Clinical trial registration : NCT02765776 and NCT03579485